Key result
Extended DOACs offer a favorable benefit-risk profile for secondary VTE prevention guided by individual risk.
Population
Patients with a history of venous thromboembolism (VTE)
Design
Review
Authors
Loading...
Supports risk-guided extended DOAC decisions after VTE; leaves open prospective validation before practice change.
The decision to continue anticoagulation beyond three months for VTE should be guided by an ongoing assessment of recurrence versus bleeding risks.
Jacek Musiał (2021) conducted a review in Venous thromboembolism (VTE). Anticoagulant treatment was evaluated. Extended anticoagulant therapy with direct oral anticoagulants offers a favorable benefit-risk profile for secondary prevention of venous thromboembolism, guided by individual recurrence and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: